Trial Profile

Molecular Analysis for Therapy Choice (MATCH)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABSK 091 (Primary) ; Adavosertib (Primary) ; Afatinib (Primary) ; Binimetinib (Primary) ; Capivasertib (Primary) ; Copanlisib (Primary) ; Crizotinib (Primary) ; Dabrafenib (Primary) ; Dasatinib (Primary) ; Defactinib (Primary) ; Erdafitinib (Primary) ; GSK 2636771 (Primary) ; Ipatasertib (Primary) ; Larotrectinib (Primary) ; Nivolumab (Primary) ; Osimertinib (Primary) ; Palbociclib (Primary) ; Pertuzumab (Primary) ; Sapanisertib (Primary) ; Sunitinib (Primary) ; Taselisib (Primary) ; Trametinib (Primary) ; Trastuzumab emtansine (Primary) ; Ulixertinib (Primary) ; Vismodegib (Primary)
Indications Adenocarcinoma; Adenoid cystic carcinoma; Advanced breast cancer; Anal cancer; Bladder cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; CNS cancer; Colorectal cancer; Endometrial cancer; Gastrointestinal cancer; Glioblastoma; Gliosarcoma; Haemangiosarcoma; Head and neck cancer; Leiomyosarcoma; Liver cancer; Lung cancer; Lymphoma; Malignant melanoma; Mesothelioma; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Perivascular epithelioid cell tumours; Prostate cancer; Renal cell carcinoma; Salivary gland cancer; Sarcoma; Solid tumours; Squamous cell cancer; Thyroid cancer; Triple negative breast cancer; Urogenital cancer; Uterine cancer
Focus Registrational; Therapeutic Use
Acronyms MATCH; NCI-MATCH; NCI-MATCH ECOG-ACRIN Trial (EAY131)

04 Jun 2024 Results(n=200) reporting the molecular profiles of ctDNA from a subset of the NCI-MATCH screened patients with gynecologic cancers, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
06 Jun 2023 Results of an analysis assessing molecular profiling of ctDNA from patients enrolled in this trial for treatment with mTOR1/2 inhibitor sapanisertib (arm M) and the Hedgehog pathway inhibitor vismodegib (arm T) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
06 Jun 2023 Results of subprotocols C1 (n=44) and C2 (n=20) assessing efficacy of crizotinib in patients with MET amplification and MET exon 14 deletion, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com